Paper. Florineth GA, Boeker AL, Bracht T et al.. Journal of Psychopharmacology, 8 Oct 2026.
Tags: Meta-analysis, Review, Psilocybin, Addiction.
MDMA for PTSD pools to g = -0.71; psilocybin for alcohol use disorder to around SMD 0.5.
The MDMA living review covers 6 RCTs and 286 participants, all MAPS-sponsored, with response risk ratio 1.35 and remission 2.25. The alcohol meta-analysis found 6 trials and only 202 participants total, of which 3 were randomized.
Pooled across six trials, psilocybin's edge on drinking is real but moderate and short-lived.
Six trials totalling 202 patients, only three randomized, give standardized mean differences of roughly 0.4-0.5 for drinks per day, percent drinking days and heavy drinking days versus control. Within-group reductions held out to 28 weeks, but those have no comparator.
How much weight it carries: Pooled estimate from six trials, only three randomized, 202 patients total; adequate to size a short-term signal, not to establish durability. (Humans, Meta-analysis, Systematic review, RCT, Small sample, n = 202)
